Crossmark

What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force

Crossref DOI link: https://doi.org/10.14283/jpad.2018.23

Published Print: 2018-07

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Aisen, P.S.

Siemers, E.

Michelson, D.

Salloway, S.

Sampaio, C.

Carrillo, M.C.

Sperling, R.

Doody, R.

Scheltens, P.

Bateman, R.

Weiner, M.

Vellas, B.
License Information

Text and Data Mining valid from 2018-07-01

Text and Data Mining valid from 2018-07-01

Version of Record valid from 2024-09-26
More Information

This article is maintained by: Elsevier

Article Title: What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force

Journal Title: The Journal of Prevention of Alzheimer's Disease

CrossRef DOI link to publisher maintained version: https://doi.org/10.14283/jpad.2018.23

Content Type: article

Copyright: Copyright © 2018 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS